XML 57 R13.htm IDEA: XBRL DOCUMENT
v3.19.2

7. SUBSEQUENT EVENTS | 6 Months Ended
--- | ---
Jun. 30, 2019
Subsequent Events [Abstract] |
SUBSEQUENT EVENTS | Amended Office Lease On July 1, 2019, the Company amended its office lease agreement related to its current office space located at 1200 Summit Ave., Suite 414, Fort Worth, TX 76102. The amended lease is effective upon completion by landlord of certain leasehold improvements (the “Commencement Date”) which were expected to be completed in late August 2019. Under the terms of the amended lease agreement, the Company will lease an additional 1,682 rentable square feet of office space which will bring the total square footage leased to 5,877. The amended lease agreement extends the original term of the lease for a period of 36 months through June 30, 2024. Upon the Commencement Date of the amended lease, the monthly base rental payments are as follows:
From |  | Through |  |  | Monthly Base Rental
Commencement Date |  |  | June 30,2020 |  |  |  | $12,243.75
July 1,2020 |  |  | June 30,2020 |  |  |  | $12,488.63
July 1,2020 |  |  | June 30,2020 |  |  |  | $12,488.63
July 1,2020 |  |  | June 30,2020 |  |  |  | $12,733.50
July 1,2020 |  |  | June 30,2020 |  |  |  | $12,978.38
BIAKŌS™ License Agreement On July 8, 2019, the Company executed a license agreement with Rochal Industries, LLC (“Rochal”) whereby Sanara acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications (the “License Agreement”). Currently, the products covered by the License Agreement are BIAKŌS™ Antimicrobial Wound Gel, and FDA cleared BIAKŌS™ Antimicrobial Skin and Wound Cleanser. A director and indirect principal shareholder of Sanara is also a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential exercise of warrants a majority shareholder. Key terms of the License Agreement include:
1. | In consideration for the license, Sanara paid to Rochal $1,000,000 and agreed to pay an additional $500,000 upon FDA clearance of the BIAKŌS™ Antimicrobial Wound Gel product for sale within the United States.
2. | Subject to the occurrence of specified Sanara financing conditions in 2019, Sanara will also pay Rochal $1,500,000, which at Sanara’s option may be in cash or Sanara Common Stock; or a combination of cash and Sanara Common Stock.
3. | Sanara will pay Rochal a royalty of:
a. | 4% of net sales of licensed products in countries in which patents are registered
b. | 2% of net sales of licensed products in countries without patent protection.
c. | The minimum annual royalty due to Rochal will be $100,000 beginning with calendar year 2020. The annual minimum royalty will increase by 10% each subsequent calendar year up to a maximum amount of $150,000.
d. | Beginning with the 2020 calendar year, Sanara will pay an additional royalty based on specific net profit targets related to the licensed products. Net profits for the licensed products are defined as net sales, less cost of goods sold (including royalties) and direct marketing and selling expenses. The additional royalty will be 25% of the amount of actual net profits in excess of the established net profit targets, subject to a maximum of $1,000,000 for any calendar year. The established net profit targets for each calendar year are:
i. | 2020 - $1,500,000
ii. | 2021 - $5,000,000
iii. | 2022 - $8,000,000
iv. | 2023 - $10,000,000
v. | 2024 - $15,000,000
vi. | Beginning in 2025 and for each calendar year thereafter, net profit targets will be equal to the immediately preceding calendar year’s net profit target incremented by the greater of (1) 50% of the U.S. dollar growth in the amount of net profit in the current year over net profit in the immediately preceding calendar year, or (2) the percentage of overall growth of the market for the category by which the licensed products are generally described.
4. | Unless previously terminated by the parties, the License Agreement will expire with the related patents in December 2031.
The foregoing summary of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the License Agreement. See Exhibit 10.1 for a full copy of the License agreement.

X
- References No definition available. + Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration